Details for Patent: 10,550,098

Which drugs does patent 10,550,098 protect, and when does it expire?

Patent 10,550,098 protects REZLIDHIA and is included in one NDA.

This patent has ninety-two patent family members in thirty-seven countries.

Summary for Patent: 10,550,098

Title:	Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
Abstract:	The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where A, U, W1, W2, W3, R1-R6, and R9 are described herein.
Inventor(s):	Jian Lin, Anna Ericsson, Ann-Marie Campbell, Gary Gustafson, Zhongguo Wang, R. Bruce Diebold, Susan Ashwell, David R. Lancia, Jr., Justin Andrew Caravella, Wei Lu
Assignee:	Forma Therapeutics Inc
Application Number:	US16/290,240
Patent Claim Types: see list of patent claims	Use; Composition; Process;

Drugs Protected by US Patent 10,550,098

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Rigel Pharms	REZLIDHIA	olutasidenib	CAPSULE;ORAL	215814-001	Dec 1, 2022		RX	Yes	Yes	10,550,098		Y

International Family Members for US Patent 10,550,098

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	101976
Australia	2015317322
Australia	2015317327